Literature DB >> 29773311

[Corneal endothelial cell therapy, a review].

V Kocaba1, O Damour2, C Auxenfans2, C Burillon3.   

Abstract

In France, endothelial dysfunction represents approximately one half of the indications for corneal transplants performed each year. However, the use of endothelial keratoplasty is limited by the technical difficulty of the procedure, a shortage of available grafts, and the potential for graft failure or rejection. These limitations are driving researchers to develop new, less invasive, and more effective therapies. Corneal endothelial cell therapy is being explored as a potential therapeutic measure, to avoid the uncertainty associated with grafting. The human cornea is an ideal tissue for cell therapy. Due to its avascular and immunologically privileged characteristics, transplanted cells are better tolerated compared with other vascularized tissues and organs. Advances in the field of stem cell engineering, particularly the development of corneal epithelial stem cell therapy for the treatment of severe ocular surface disease, have aroused a massive interest in adapting cell therapy techniques to corneal endothelial cells. This chapter, based on a review of the literature, aims at educating the reader on the latest research in the field of corneal endothelial cell therapy.
Copyright © 2018 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Cell therapy; Cellules souches cornéennes endothéliales; Corneal endothelial dysfunction; Corneal endothelial dystrophy; Corneal endothelial stem cells; Dysfonction cornéenne endothéliale; Dystrophie cornéenne endothéliale; Thérapie cellulaire

Mesh:

Year:  2018        PMID: 29773311     DOI: 10.1016/j.jfo.2018.01.002

Source DB:  PubMed          Journal:  J Fr Ophtalmol        ISSN: 0181-5512            Impact factor:   0.818


  1 in total

Review 1.  Mesenchymal stem cell-derived extracellular vesicles as a new therapeutic strategy for ocular diseases.

Authors:  Bo Yu; Xiao-Rong Li; Xiao-Min Zhang
Journal:  World J Stem Cells       Date:  2020-03-26       Impact factor: 5.326

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.